IRB Barcelona researcher Roger Gomis receives an award for his work on cancer
The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.
The award ceremony will be held in Valencia on 6, 7 and 8 November.
The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.
ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.
“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.
The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.
More information: http://www.aseica.es/
Related content
News
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
